Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Paychex, Inc. (PAYX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Paychex, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Paychex, Inc. trades at $106.61 (market cap $38.44B). The key difference: Paychex, Inc. is far larger — about 8.6× ACADIA Pharmaceuticals Inc.'s market cap, and Paychex, Inc. pays a 4.4% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PAYX | |
|---|---|---|
Market Cap | $4.49B | $38.44B |
Sector | Health | Industrials |
52-Week High | $28.06 | $147.99 |
52-Week Low | $20.06 | $85.57 |
Enterprise Value | $3.69B | $41.92B |
Dividend Yield | — | 4.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Paychex (PAYX) trades at $108.12, up 1.66% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI suggests mild overbought conditions. Fundamentally, the company maintains robust profitability with 27% net margins and 44.8% ROE, supported by steady revenue growth and strong cash flow generation.
The outlook remains positive with analyst consensus at $110 target and continued AI-driven growth initiatives. However, elevated valuation multiples and potential macroeconomic headwinds to small business hiring present risks. The stock offers a compelling combination of growth execution and shareholder returns through dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
